GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AC Immune SA (FRA:IMR) » Definitions » Cyclically Adjusted PB Ratio

AC Immune (FRA:IMR) Cyclically Adjusted PB Ratio : 0.64 (As of Jun. 02, 2025)


View and export this data going back to 2016. Start your Free Trial

What is AC Immune Cyclically Adjusted PB Ratio?

As of today (2025-06-02), AC Immune's current share price is €1.50. AC Immune's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 was €2.35. AC Immune's Cyclically Adjusted PB Ratio for today is 0.64.

The historical rank and industry rank for AC Immune's Cyclically Adjusted PB Ratio or its related term are showing as below:

FRA:IMR' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 0.57   Med: 1.03   Max: 1.31
Current: 0.67

During the past years, AC Immune's highest Cyclically Adjusted PB Ratio was 1.31. The lowest was 0.57. And the median was 1.03.

FRA:IMR's Cyclically Adjusted PB Ratio is ranked better than
66.67% of 672 companies
in the Biotechnology industry
Industry Median: 1.475 vs FRA:IMR: 0.67

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

AC Immune's adjusted book value per share data for the three months ended in Mar. 2025 was €0.988. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.35 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


AC Immune Cyclically Adjusted PB Ratio Historical Data

The historical data trend for AC Immune's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AC Immune Cyclically Adjusted PB Ratio Chart

AC Immune Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 1.04

AC Immune Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 1.46 1.04 0.73

Competitive Comparison of AC Immune's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, AC Immune's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AC Immune's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AC Immune's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where AC Immune's Cyclically Adjusted PB Ratio falls into.


;
;

AC Immune Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

AC Immune's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=1.50/2.35
=0.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AC Immune's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, AC Immune's adjusted Book Value per Share data for the three months ended in Mar. 2025 was:

Adj_Book=Book Value per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=0.988/107.7224*107.7224
=0.988

Current CPI (Mar. 2025) = 107.7224.

AC Immune Quarterly Data

Book Value per Share CPI Adj_Book
201506 0.000 100.464 0.000
201509 0.000 99.785 0.000
201512 1.183 99.386 1.282
201603 1.069 99.475 1.158
201606 1.500 100.088 1.614
201609 2.416 99.604 2.613
201612 2.332 99.380 2.528
201703 2.182 100.040 2.350
201706 1.952 100.285 2.097
201709 1.712 100.254 1.840
201712 1.744 100.213 1.875
201803 1.578 100.836 1.686
201806 1.252 101.435 1.330
201809 2.522 101.246 2.683
201812 2.330 100.906 2.487
201903 3.166 101.571 3.358
201906 3.634 102.044 3.836
201909 3.740 101.396 3.973
201912 3.473 101.063 3.702
202003 3.487 101.048 3.717
202006 3.264 100.743 3.490
202009 3.017 100.585 3.231
202012 2.771 100.241 2.978
202103 2.579 100.800 2.756
202106 2.382 101.352 2.532
202109 2.272 101.533 2.411
202112 2.670 101.776 2.826
202203 2.506 103.205 2.616
202206 2.371 104.783 2.438
202209 2.359 104.835 2.424
202212 2.048 104.666 2.108
202303 1.846 106.245 1.872
202306 1.710 106.576 1.728
202309 1.550 106.570 1.567
202312 1.717 106.461 1.737
202403 1.515 107.355 1.520
202406 1.287 107.991 1.284
202409 1.399 107.468 1.402
202412 1.198 107.128 1.205
202503 0.988 107.722 0.988

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


AC Immune  (FRA:IMR) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


AC Immune Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of AC Immune's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


AC Immune Business Description

Industry
Traded in Other Exchanges
Address
EPFL Innovation Park, Building B, Lausanne, CHE, 1015
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

AC Immune Headlines

No Headlines